![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC6A4 |
Gene summary for SLC6A4 |
![]() |
Gene information | Species | Human | Gene symbol | SLC6A4 | Gene ID | 6532 |
Gene name | solute carrier family 6 member 4 | |
Gene Alias | 5-HTT | |
Cytomap | 17q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | B2R7Y7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6532 | SLC6A4 | HCC1 | Human | Liver | HCC | 6.31e-22 | 1.30e+00 | 0.5336 |
6532 | SLC6A4 | HCC2 | Human | Liver | HCC | 2.51e-23 | 1.37e+00 | 0.5341 |
6532 | SLC6A4 | HCC5 | Human | Liver | HCC | 2.22e-28 | 1.26e+00 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:000758421 | Liver | HCC | response to nutrient | 111/7958 | 174/18723 | 1.10e-08 | 2.73e-07 | 111 |
GO:000963622 | Liver | HCC | response to toxic substance | 153/7958 | 262/18723 | 1.37e-07 | 2.58e-06 | 153 |
GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
GO:000762321 | Liver | HCC | circadian rhythm | 117/7958 | 210/18723 | 7.29e-05 | 6.54e-04 | 117 |
GO:00323552 | Liver | HCC | response to estradiol | 81/7958 | 141/18723 | 2.39e-04 | 1.79e-03 | 81 |
GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
GO:00459263 | Liver | HCC | negative regulation of growth | 129/7958 | 249/18723 | 1.81e-03 | 9.37e-03 | 129 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC6A4 | SNV | Missense_Mutation | c.1609N>A | p.Trp537Arg | p.W537R | P31645 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
SLC6A4 | SNV | Missense_Mutation | rs764936225 | c.1802N>T | p.Pro601Leu | p.P601L | P31645 | protein_coding | deleterious(0) | possibly_damaging(0.638) | TCGA-DD-A113-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SLC6A4 | SNV | Missense_Mutation | novel | c.323T>A | p.Ile108Lys | p.I108K | P31645 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-DD-AACL-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | c.830N>A | p.Ser277Tyr | p.S277Y | P31645 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
SLC6A4 | SNV | Missense_Mutation | novel | c.845G>T | p.Trp282Leu | p.W282L | P31645 | protein_coding | deleterious(0.01) | probably_damaging(0.99) | TCGA-55-A490-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
SLC6A4 | SNV | Missense_Mutation | novel | c.839N>C | p.Val280Ala | p.V280A | P31645 | protein_coding | tolerated(0.16) | possibly_damaging(0.557) | TCGA-55-A4DG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | rs374583307 | c.1201G>A | p.Ala401Thr | p.A401T | P31645 | protein_coding | tolerated(0.61) | benign(0.01) | TCGA-78-7152-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SLC6A4 | SNV | Missense_Mutation | c.299N>T | p.Gly100Val | p.G100V | P31645 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-86-A456-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SLC6A4 | SNV | Missense_Mutation | rs199873504 | c.1262N>T | p.Thr421Ile | p.T421I | P31645 | protein_coding | deleterious(0.05) | probably_damaging(0.942) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
SLC6A4 | SNV | Missense_Mutation | novel | c.1631T>C | p.Ile544Thr | p.I544T | P31645 | protein_coding | deleterious(0) | benign(0.107) | TCGA-21-1080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | DULOXETINE | DULOXETINE | ||
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | buprenorphine | BUPRENORPHINE | 29333880 | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178104007 | LEVOMILNACIPRAN | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | berberine | BERBERINE | 21647174 | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178103894 | VENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | DESVENLAFAXINE | DESVENLAFAXINE | ||
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | ethanol | ALCOHOL | 31595439 | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | VENLAFAXINE | VENLAFAXINE | ||
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | AMOXAPINE | AMOXAPINE | ||
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | AMOXAPINE | AMOXAPINE |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |